<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="16415">Protopine</z:chebi>, an <z:chebi fb="0" ids="16092">isoquinoline</z:chebi> alkaloidis, is known to produce many effects such as vasodilation, down-regulation of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> levels in brain and decrease of intracellular calcium </plain></SENT>
<SENT sid="1" pm="."><plain>However, so far there is no report on the effect of <z:chebi fb="0" ids="16415">protopine</z:chebi> in <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, the effect of <z:chebi fb="0" ids="16415">protopine</z:chebi> on the focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> was investigated in rats </plain></SENT>
<SENT sid="3" pm="."><plain>Male Sprague-Dawley rats were divided into five groups: sham-operated group, vehicle-treated group and three doses of <z:chebi fb="0" ids="16415">protopine</z:chebi>-treated groups (0.98, 1.96 and 3.92 mg/kg) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="16415">Protopine</z:chebi> was intraperitoneally administered to rats once daily for 3 days prior to the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> and 0.9% <z:mpath ids='MPATH_458'>normal</z:mpath> saline to rats in the vehicle-treated group in the same pattern </plain></SENT>
<SENT sid="5" pm="."><plain>Rats in the sham-operated group were given 0.9% <z:mpath ids='MPATH_458'>normal</z:mpath> saline without the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> was induced by the middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 24 hr via the intraluminal filament technique </plain></SENT>
<SENT sid="7" pm="."><plain>The results showed that pre-treatment with <z:chebi fb="0" ids="16415">protopine</z:chebi> reduced the <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> ratio and serum <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase activity, and improved the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced neurological deficit score and histological changes of brain in a dose-dependent manner </plain></SENT>
<SENT sid="8" pm="."><plain>The further studies demonstrated that <z:chebi fb="0" ids="16415">protopine</z:chebi> increased <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase activity in serum, and decreased total calcium and terminal deoxynucleotidyl transferase-mediated <z:chebi fb="0" ids="17625">dUTP</z:chebi> nick end labelling (TUNEL)-positive cells in the ischaemic brain tissue in the middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> rats </plain></SENT>
<SENT sid="9" pm="."><plain>The results indicate that <z:chebi fb="0" ids="16415">protopine</z:chebi> is able to produce an effective protection on the injury caused by the focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> in rats possibly through the multiple effects of calcium antagonism, antioxidation and <z:hpo ids='HP_0000716'>depression</z:hpo> of cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
</text></document>